SEC Form 4 · accession 0000905148-26-004079
RIGEL PHARMACEUTICALS INC · RIGL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David A Santos
Officer — EVP, Chief Commercial Officer
Period of report
Sep 1, 2026
Accepted (ET)
Sep 3, 2026 · 7:01 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001034842
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 1, 2026 | F | 874 | $47.50 | D | 61,622 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 500 shares acquired under the Issuer's stock purchase plan.